Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890756 | 0.90 | HIF1A (0.48) | HIF1AHTTCDK4CYP2D6ABCB1 | |
| SCHEMBL21431103 | 0.85 | TK1 (0.46) | POLBNPC1 | |
| SCHEMBL15281845 | 0.85 | KIF11 (0.49) | — | |
| SCHEMBL19522241 | 0.85 | SLC6A1 (0.44) | — | |
| SCHEMBL3490250 | 0.85 | KIF11 (0.49) | — | |
| SCHEMBL19500457 | 0.84 | KIF11 (0.40) | CYP2D6HTR2AALDH1A1HSD17B10 | |
| SCHEMBL16472146 | 0.83 | KIF11 (0.50) | — | |
| SCHEMBL27081312 | 0.83 | KIF11 (0.50) | — | |
| SCHEMBL7716732 | 0.82 | KIF11 (0.41) | — | |
| SCHEMBL18349848 | 0.82 | TK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092739-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | SIMA THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092739-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | SIMA THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7893302-B2 | novel cationic lipids based on 4-(aminomethyl)-1,2-bis-(fatty ether or ester)-benzene | SIRNA THERAPEUTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893302-B2 | novel cationic lipids based on 4-(aminomethyl)-1,2-bis-(fatty ether or ester)-benzene | SIRNA THERAPEUTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100105933-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | CHEN TONGQIAN | 2010-04-29 | — | — | US | disclosed |
| US-20100105933-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | CHEN TONGQIAN | 2010-04-29 | — | — | US | disclosed |
| US-7691405-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691405-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100063308-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | BANK OF AMERICA, N.A. | 2010-03-11 | — | — | US | disclosed |
| US-20100063308-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | BANK OF AMERICA, N.A. | 2010-03-11 | — | — | US | disclosed |
| US-20080188675-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | SIRNA THERAPEUTICS INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188675-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | SIRNA THERAPEUTICS INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-7404969-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7404969-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1922300-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | Sirna Therapeutics Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2007086883-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | SIRNA THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007086881-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | SIRNA THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20060240554-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092739-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | PHAX, CETP, LIPC | HIF1A 1481/4885HTT 1740/4885POLB 1178/4885 |
| US-20100063308-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, CETP, LIPC | HIF1A 1481/4885HTT 1740/4885POLB 1178/4885 |
| US-20060240554-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | PHAX, CETP, LIPC | HIF1A 1481/4885HTT 1740/4885POLB 1178/4885 |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | PHAX, CETP, LIPC | HIF1A 1534/4885HTT 1758/4885POLB 1201/4885 |
| US-20100105933-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, CETP, LIPC | HIF1A 1534/4885HTT 1758/4885POLB 1201/4885 |
| US-20080188675-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, CETP, LIPC | HIF1A 1481/4885HTT 1740/4885POLB 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.